The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.
A manufacturing problem in millions of Abbott glucose sensors has been tied to at least seven deaths and hundreds of injuries worldwide.
The twiist (left) and Eversense E3 (right) systems. [Images courtesy of Sequel Med Tech and Senseonics] Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and ...
Researchers linked insulin resistance to 12 types of cancer, with uterine cancer showing the strongest connection at 134% increased risk. A new AI tool outperformed BMI alone in predicting cancer risk ...
The Portal Pump, an implantable system for closed-loop insulin delivery. [Image from Portal Diabetes] Portal Diabetes announced today that it received FDA breakthrough device designation for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results